Trending...
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
~ A recent study presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition has found that patients with mantle cell lymphoma (MCL) who have no detectable cancer after initial therapy do not experience any survival benefit from undergoing a stem cell transplant compared to receiving maintenance therapy alone.
The trial, known as EA4151, was stopped early after an interim analysis was conducted when the study had followed patients for a median of 2.7 years. The results showed that patients who tested negative for minimal residual disease (MRD) with an ultra-high sensitivity blood test did not need to undergo a stem cell transplant or the high-dose chemotherapy regimen typically used to prepare for a transplant.
Lead author of the study, Dr. Timothy S. Fenske, stated that these findings suggest that physicians can feel comfortable omitting the transplant in MRD-negative patients. He also noted that in today's treatment landscape for MCL, good outcomes can be achieved without the high-dose chemotherapy and transplant. However, for patients who remain MRD-positive following induction therapy, a stem cell transplant may still be considered.
More on Wisconsin Eagle
MCL is a rare and aggressive blood cancer that primarily affects older adults. After initial chemotherapy, doctors often recommend a stem cell transplant to further reduce the level of residual lymphoma. However, this practice is based on studies conducted before newer and more effective treatments such as chemotherapy, immune therapy, and targeted therapies were available.
The trial enrolled 650 patients between 2017-2024 who were in their first remission after initial treatment for MCL. The participants had a median age of 60 years and were predominantly male and white. Each patient's remission status was assessed using various tests including PET/CT scans, bone marrow biopsies, and highly sensitive blood tests.
The patients were then divided into three groups based on their test results: MRD-negative (no evidence of cancer), MRD-positive (evidence of cancer in one or more cells per million), or MRD-indeterminate (testing incomplete or evidence of cancer in greater than zero but less than one cell per million).
Of the 516 patients who tested MRD-negative, they were randomly assigned to receive either a stem cell transplant and three years of maintenance rituximab or three years of maintenance rituximab alone. The remaining patients (MRD-positive and MRD-indeterminate) were assigned to receive a stem cell transplant and three years of maintenance rituximab.
More on Wisconsin Eagle
The interim analysis showed no significant difference in overall survival rates between the two groups in the MRD-negative category. With a median follow-up of 2.7 years, the overall survival rate was 82.1% for those who received a stem cell transplant and 82.7% for those who received maintenance therapy alone. The rate of survival without disease progression was also similar between the two groups.
Dr. Fenske emphasized that a stem cell transplant can be a difficult process for patients, with potential complications being especially risky for older individuals. He believes that if similar outcomes can be achieved without undergoing a transplant, it would be a significant step forward in improving treatment for MCL.
In conclusion, this study suggests that for MCL patients who test negative for minimal residual disease after initial therapy, undergoing a stem cell transplant may not provide any additional survival benefit compared to receiving maintenance therapy alone. This finding may lead to changes in current treatment recommendations and improve outcomes for these patients.
The trial, known as EA4151, was stopped early after an interim analysis was conducted when the study had followed patients for a median of 2.7 years. The results showed that patients who tested negative for minimal residual disease (MRD) with an ultra-high sensitivity blood test did not need to undergo a stem cell transplant or the high-dose chemotherapy regimen typically used to prepare for a transplant.
Lead author of the study, Dr. Timothy S. Fenske, stated that these findings suggest that physicians can feel comfortable omitting the transplant in MRD-negative patients. He also noted that in today's treatment landscape for MCL, good outcomes can be achieved without the high-dose chemotherapy and transplant. However, for patients who remain MRD-positive following induction therapy, a stem cell transplant may still be considered.
More on Wisconsin Eagle
- Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
- Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th
- Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
- Most Indiana Plane Crashes Happen Away from the State's Major Airports
- L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
MCL is a rare and aggressive blood cancer that primarily affects older adults. After initial chemotherapy, doctors often recommend a stem cell transplant to further reduce the level of residual lymphoma. However, this practice is based on studies conducted before newer and more effective treatments such as chemotherapy, immune therapy, and targeted therapies were available.
The trial enrolled 650 patients between 2017-2024 who were in their first remission after initial treatment for MCL. The participants had a median age of 60 years and were predominantly male and white. Each patient's remission status was assessed using various tests including PET/CT scans, bone marrow biopsies, and highly sensitive blood tests.
The patients were then divided into three groups based on their test results: MRD-negative (no evidence of cancer), MRD-positive (evidence of cancer in one or more cells per million), or MRD-indeterminate (testing incomplete or evidence of cancer in greater than zero but less than one cell per million).
Of the 516 patients who tested MRD-negative, they were randomly assigned to receive either a stem cell transplant and three years of maintenance rituximab or three years of maintenance rituximab alone. The remaining patients (MRD-positive and MRD-indeterminate) were assigned to receive a stem cell transplant and three years of maintenance rituximab.
More on Wisconsin Eagle
- Mom Era, Still That Girl: Family Art Tees 25% Off
- Fashion vs. Fascism - Because Democracy Should Always Be In Style
- Lee Gunn IV Shares Lessons From 40 Years in the Courtroom on PodNumbra Podcast
- Michael H. Kaplan Recognized for 17 Years on PHPA Workers' Compensation Panel and Advocacy for Professional Athletes
- International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
The interim analysis showed no significant difference in overall survival rates between the two groups in the MRD-negative category. With a median follow-up of 2.7 years, the overall survival rate was 82.1% for those who received a stem cell transplant and 82.7% for those who received maintenance therapy alone. The rate of survival without disease progression was also similar between the two groups.
Dr. Fenske emphasized that a stem cell transplant can be a difficult process for patients, with potential complications being especially risky for older individuals. He believes that if similar outcomes can be achieved without undergoing a transplant, it would be a significant step forward in improving treatment for MCL.
In conclusion, this study suggests that for MCL patients who test negative for minimal residual disease after initial therapy, undergoing a stem cell transplant may not provide any additional survival benefit compared to receiving maintenance therapy alone. This finding may lead to changes in current treatment recommendations and improve outcomes for these patients.
0 Comments
Latest on Wisconsin Eagle
- European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
- VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
- Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
- Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
- DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
- LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
- Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow